New model systems
Developing improved and sustainable model systems for predicting product safety
Therapy improvement
Enhancing gene therapy vectors for better immune evasion and stability
Regulatory engagement
Establishing a comprehensive database on safety and efficacy of advanced therapies
About ARDAT
ARDAT is a new consortium of 34 international partners from academia, industry, and small/medium enterprises whose aim is to develop and provide tools that will advance our knowledge in the field of viral gene/cell therapy and so accelerate the development of new treatments for rare diseases.
Coordinated by Dr. Martin Schulz of @pfizer & Prof. Mimoun Azzouz of @sheffielduni, ARDAT is a private-public partnership aiming to develop safer and more effective gene therapies for rare diseases. ARDAT is funded by @IHIEurope, @HorizonEU (grant agreement 945473) & @EFPIA. pic.twitter.com/SorZjevGEj
— ARDAT-Accelerating Research & Innovation for ATMPs (@AAtmps) February 6, 2024
Project structure
ARDAT
Accelerating Research & Development for Advanced Therapies
Work package 1
Project management to specify processes and principles
Work package 2
Standardized models for predicting product immunogenicity
Work package 3
Understanding of gene/cell therapy drug metabolism
Work package 4
Clinical factors around pre-existing immunity
Project structure
Work package 1
Project management to specify processes and principles
Work package 2
Standardized models for predicting product immunogenicity
Work package 3
Understanding of gene/cell therapy drug metabolism
Work package 4
Clinical factors around pre-existing immunity
Work package 5
Engagement with regulators and database development
Principal project objectives
Pre-clinical studies
Developing standardized models for predicting immunogenicity
Vector enhancement
Understanding gene/cell therapy drug molecular stability and metabolism
Clinical research
Investigating clinical factors around pre-existing immunity
Data Processing & Analysis
Establish a comprehensive and sustainable database on safety and efficacy of advanced therapies